<div><p><b>Background:</p> </b><div><p><span lang="EN-US">Obesity, metabolic syndrome, and non-alcoholic fatty liver disease (NAFLD) are becoming increasingly prevalent. Bariatric surgery, combining weight loss with metabolic improvements, may represent an effective treatment for these disease entities in obese patients with single anastomosis doudeno-ileal bypass with sleeve gastrectomy (SADI-S) representing a novel bariatric procedure.

<div><p><strong><b>Background:</strong> </b>Heterogeneity among patients with acute-on-chronic liver failure (ACLF) confer variable outcomes (mortality-range: 0-100%). While prognostic scores capture the known associations, machine learning (ML) can identify the intricate hidden patterns between patient characteristics without any explicit hypothesis or labelling that remain unexplored in ACLF. We employed ML to explore, describe, and predict unknown clusters in ACLF patients.</p>
<p></p>

<div><p><b>Background:<span> </b>Direct-acting antiviral (DAA) treatment enables almost all patients with hepatitis C virus (HCV), including those with decompensated cirrhosis to achieve sustained virologic response (SVR), and improves prognosis in SVR patients. However, factors associated with long-term prognosis after SVR are unclear. The aim of this study is to clarify the risk factors for long-term prognosis according to liver-related and non-liver-related death.</span></p>

<div><p><b>Background:<span> </b>Patients with decompensated cirrhosis have poor quality of life and complex care needs that could be addressed with existing services; but the fragmented healthcare system does not provide the necessary coordination to best care for this population. Collaborative care models (CCM) can bridge this gap by providing coordinated, personalized care using care coordinators. In this pilot randomized trial, we developed and tested a CCM for cirrhosis: The Cirrhosis Medical Home (CMH).</span></p>

<div><p><b>Background: </b>Pediatric acute liver failure (PALF) remains a poorly-characterized disease entity that affects children of all ages. Emerging data supports an underlying immune-mediated process driving progression and severity. Up to 25% of patients will require liver transplantation (LT), yet there are no reliable indicators of disease trajectory to guide clinicians. </p>

<div><p><b>Background: </b>H<span>epatic stellate cells (HSCs) are the main drivers of liver fibrosis. During The Liver Meeting 2022, we demonstrated that glycolysis deficiency selectively in HSCs attenuated liver fibrosis <em>in vivo</em>. The aim of the present study is to understand how HSC-specific glycolysis promotes liver fibrosis by altering signaling pathways and HSC interactions with the surrounding cell types in a spatial manner.</span></p>

<div><p><b>Background:</p> </b><p>As the prevalence of obesity and MASH continues to grow, novel treatment options are needed to prevent progression as there are currently no medications approved to treat MASH. Weight loss has been shown to be an effective treatment with a 5% weight loss reversing steatosis and a 10% weight loss reversing liver fibrosis. Clinical trials using lifestyle-based weight loss interventions in MASH have been shown to achieve &gt;5% total body weight loss (TBWL) in 30% of patients and &gt;10% TBWL in 10% of patients.

<div><p><strong><b>Background:</strong> </b></p>

<div><p><b>Background:</p> </b><p>Cirrhosis now has the 10th highest mortality rate worldwide. Most cirrhosis deaths are caused by the emergence of clinical decompensation, and 4%–12% of those who have the disease, experience at least one episode of decompensation per year<strong>.</strong> These patients are highly susceptible to infections due to increased systemic inflammation leading to kidney failure and death.

<div><p><b>Background:</p> </b><p>Continuous renal replacement therapy (CRRT) is the preferred mode of dialysis in critically ill hemodynamically unstable patients and in addition removes the inflammatory cytokines that accumulate in sepsis. Sustained low-efficiency dialysis (SLED) is a hybrid modality of intermittent dialysis with the advantage of metabolic control, hemodynamic stability, at a reduced cost.